pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·1d ago·1 min read
save

Experts debate extra regulation for low-risk digital wellness devices

Aug 4, 2026·read at raps ↗RegulatoryNeutral

Two recent papers published in JAMA have highlighted concerns about low-risk digital health technologies that consumers use.

Experts say that even though these tools are considered low-risk, they may warrant tighter regulatory oversight to protect users.

The debate focuses on finding a balance between encouraging innovation and ensuring safety, with no specific regulatory actions announced yet.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “Experts question need for more regulatory scrutiny of digital wellness devices”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoRecon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelcaraps
  • 1d agoFDA seeks feedback on quantitative medicine networkraps
  • 2d agoRecon: AstraZeneca, BMS discuss merger; FDA broadens indication for Novartis’ Pluvictoraps
  • 2d agoAsia-Pacific Roundup: TGA seeks feedback on planned adoption of 11 international scientific guidelinesraps
  • 2d agoExpert sees shift to ‘ecosystem-centric assurance’ under FDA’s distributed manufacturing ruleraps